Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel in Unresectable or Metastatic GEP-NET (China)
CTR20210552Phase 3Completed
- Sponsor
- Ipsen
- Start
- Apr 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lanreotide in Gastroenteropancreatic Carcinoid Tumor, sponsored by Ipsen. Started Apr 2021; status: completed.
02
Drugs
lanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20210552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210552.